New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
UTHealth Houston clinical trial therapy shrinks tumor of pancreatic cancer patient

UTHealth Houston clinical trial therapy shrinks tumor of pancreatic cancer patient

Demetrios Stroubakis, 55, thought he was having a gallbladder attack when he arrived at the emergency room in August 2021 with jaundice. Instead, he was shocked to be diagnosed with pancreatic cancer.
World medicine November 09,2023
UTHealth Houston clinical trial therapy shrinks tumor of pancreatic cancer patient

UTHealth Houston clinical trial therapy shrinks tumor of pancreatic cancer patient

Demetrios Stroubakis, 55, thought he was having a gallbladder attack when he arrived at the emergency room in August 2021 with jaundice. Instead, he was shocked to be diagnosed with pancreatic cancer.
World medicine November 09,2023
Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

New research in the October 2023 issue ofJNCCN-;Journal of the National Comprehensive Cancer Networkfinds that intensive local-regional treatment to remove as much tumor as possible (known
World medicine November 09,2023
Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

New research in the October 2023 issue ofJNCCN-;Journal of the National Comprehensive Cancer Networkfinds that intensive local-regional treatment to remove as much tumor as possible (known
World medicine November 09,2023
Hackensack University Medical Center establishes new Center for Weight Loss and Metabolic Health

Hackensack University Medical Center establishes new Center for Weight Loss and Metabolic Health

Hackensack University Medical Center has established the Center for Weight Loss and Metabolic Health, an integrated program to help people who have struggled to lose weight to achieve and maintain the
World medicine November 09,2023
Hackensack University Medical Center establishes new Center for Weight Loss and Metabolic Health

Hackensack University Medical Center establishes new Center for Weight Loss and Metabolic Health

Hackensack University Medical Center has established the Center for Weight Loss and Metabolic Health, an integrated program to help people who have struggled to lose weight to achieve and maintain the
World medicine November 09,2023
Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera

Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera

Rusfertide (PTG-300) demonstrated freedom from phlebotomy, sustained hematocrit control, and 12-week treatment completion in 69.2% (n = 18/26) vs 18.5% (n = 5/27) of patients with phlebotomy-dependent
World medicine November 09,2023
Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera

Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera

Rusfertide (PTG-300) demonstrated freedom from phlebotomy, sustained hematocrit control, and 12-week treatment completion in 69.2% (n = 18/26) vs 18.5% (n = 5/27) of patients with phlebotomy-dependent
World medicine November 09,2023
Study sheds new light on the relationship between autism traits and mental health in middle childhood

Study sheds new light on the relationship between autism traits and mental health in middle childhood

A long-term study by UC Davis Health researchers sheds new light on the relationship between autism traits and mental health in middle childhood. The paper, published in the journalAutism, finds
World medicine November 09,2023
Study sheds new light on the relationship between autism traits and mental health in middle childhood

Study sheds new light on the relationship between autism traits and mental health in middle childhood

A long-term study by UC Davis Health researchers sheds new light on the relationship between autism traits and mental health in middle childhood. The paper, published in the journalAutism, finds
World medicine November 09,2023
NOX-A12 Plus Bevacizumab and Radiotherapy Shows Sustained Survival in Glioblastoma

NOX-A12 Plus Bevacizumab and Radiotherapy Shows Sustained Survival in Glioblastoma

The addition of the CXCL12 inhibitor NOX-A12 (olaptesed pegol) to standard frontline therapy with radiation and bevacizumab (Avastin) led to an overall survival (OS) rate of 83% (n = 5/6) at a median
World medicine November 09,2023
NOX-A12 Plus Bevacizumab and Radiotherapy Shows Sustained Survival in Glioblastoma

NOX-A12 Plus Bevacizumab and Radiotherapy Shows Sustained Survival in Glioblastoma

The addition of the CXCL12 inhibitor NOX-A12 (olaptesed pegol) to standard frontline therapy with radiation and bevacizumab (Avastin) led to an overall survival (OS) rate of 83% (n = 5/6) at a median
World medicine November 09,2023
Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

A single administration of lisocabtagene maraleucel (Breyanzi; liso-cel) provided deep and durable remissions when used as third-line treatment in patients with relapsed or refractory follicular lymph
World medicine November 09,2023
Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

Liso-Cel Elicits ORR of 97% in Relapsed/Refractory Follicular Lymphoma

A single administration of lisocabtagene maraleucel (Breyanzi; liso-cel) provided deep and durable remissions when used as third-line treatment in patients with relapsed or refractory follicular lymph
World medicine November 09,2023
Calorie restriction may rejuvenate muscles and activate biological pathways for healthy aging

Calorie restriction may rejuvenate muscles and activate biological pathways for healthy aging

Reducing overall calorie intake may rejuvenate your muscles and activate biological pathways important for good health, according to researchers at the National Institutes of Health and their colleagu
World medicine November 09,2023
Calorie restriction may rejuvenate muscles and activate biological pathways for healthy aging

Calorie restriction may rejuvenate muscles and activate biological pathways for healthy aging

Reducing overall calorie intake may rejuvenate your muscles and activate biological pathways important for good health, according to researchers at the National Institutes of Health and their colleagu
World medicine November 09,2023
Research suggests potential connection between gut bacteria and onset of colorectal lesions and cancers

Research suggests potential connection between gut bacteria and onset of colorectal lesions and cancers

New research has identified significant variations in the gut microbiome of individuals who developed pre-cancerous colonic lesions, suggesting a potential connection between gut bacteria and the onse
World medicine November 09,2023
Research suggests potential connection between gut bacteria and onset of colorectal lesions and cancers

Research suggests potential connection between gut bacteria and onset of colorectal lesions and cancers

New research has identified significant variations in the gut microbiome of individuals who developed pre-cancerous colonic lesions, suggesting a potential connection between gut bacteria and the onse
World medicine November 09,2023
Gedatolisib Triplet Shows Early Efficacy in Previously Untreated ER+/HER2– Breast Cancer

Gedatolisib Triplet Shows Early Efficacy in Previously Untreated ER+/HER2– Breast Cancer

The addition of gedatolisib to palbociclib (Ibrance) and letrozole produced durable responses with comparable safety to that observed with palbociclib and letrozole alone in treatment-naïve patients w
World medicine November 09,2023
Gedatolisib Triplet Shows Early Efficacy in Previously Untreated ER+/HER2– Breast Cancer

Gedatolisib Triplet Shows Early Efficacy in Previously Untreated ER+/HER2– Breast Cancer

The addition of gedatolisib to palbociclib (Ibrance) and letrozole produced durable responses with comparable safety to that observed with palbociclib and letrozole alone in treatment-naïve patients w
World medicine November 09,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com